Increased epithelial cadherin expression among Japanese intestinal-type gastric cancers compared with specimens from American patients of European descent

American Surgeon

Volumn 72, Issue 4, 2006, Pages 332-338

  Theuer, Charles P ^a,e   Al Kuran, Rasha ^b   Akiyama, Yoshiyuki ^c   Okumura, Minoru ^d   Ziogas, Al ^a   Carpenter, Philip M ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Odaira Memorial Tokyo Hitachi Hospital   (Japan)

^d Hitachi General Hospital   (Japan)

^e NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; FORMALDEHYDE; PARAFFIN; UVOMORULIN; CADHERIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; KI 67 ANTIGEN; PROTEIN P53;

AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CONTROLLED STUDY; EUROPEAN AMERICAN; FEMALE; GASTRECTOMY; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; JAPANESE; MALE; PROGNOSIS; PROTEIN EXPRESSION; STOMACH ADENOCARCINOMA; ADENOCARCINOMA; ASIAN; CAUCASIAN; COMPARATIVE STUDY; GENETICS; JAPAN; METABOLISM; MIDDLE AGED; PATHOLOGY; STOMACH TUMOR; UNITED STATES;

ADENOCARCINOMA; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CADHERINS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; JAPAN; KI-67 ANTIGEN; MALE; MIDDLE AGED; RECEPTOR, ERBB-2; STOMACH NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53; UNITED STATES;

EID: 33646936913     PISSN: 00031348     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (73)

1. Fielding JWL. Gastric cancer: different diseases. Br J Surg 1989;76:1227.
2. Meyers WC, Damiano RJ, Postlewait RW, Rotolo FS. Adenocarcinoma of the stomach: changing patterns over the last 4 decades. Ann Surg 1987;205:1-8.
3. Kampschoer GHM, Nakajima T, van de Velde CJH. Changing patterns in gastric adenocarcinoma. Br J Surg 1989;76:914-6.
4. Cady B, Rossi RL, Silverman ML, et al. Gastric adenocarcinoma. A disease in transition. Ann Surg 1989;124:303-8.
5. Bonenkamp JJ, van de Velde CJH, Kampschoer GHM, et al. Comparison of factors influencing the prognosis of Japanese, German, and Dutch gastric cancer patients. World J Surg 1993;17:410-5.
6. Roder JD, Bonenkamp JJ, Craven J, et al. Lymphadenectomy for gastric cancer in clinical trials: update. World J Surg 1995;19:546-53.
7. Mok YJ, Koo BW, Whang CW, et al. Cancer of the stomach: a review of two hospitals in Korea and Japan. World J Surg 1993;17:777-82.
8. Wang JY, Hsieh JS, Huang CJ, et al. Clinicopathologic study of advanced gastric cancer without serosal invasion in young and old patients. J Surg Oncol 1996;63:36-40.
9. Maruyama K, Sasako M, Kinoshita T, et al. Surgical treatment for gastric cancer: the Japanese approach. Semin Oncol 1996;23:360-8,
10. Bunt AMG, Hermans J, Smit VTHBM, et al. Surgical/pathologic-stage migration confounds comparisons of gastric cancer survival rates between Japan and western countries. J Clin Oncol 1995;13:19-25.
11. Shiu MH, Moore E, Sanders M, et al. Influence of the extent of resection on survival after curative treatment of gastric carcinoma. Arch Surg 1987;122:1347-51.
12. Siewert JR, Roder JD, Bottcher K, et al. Prognostic relevance of systemic lymph node dissection in gastric carcinoma. Br J Surg 1993;80:1015.
13. Wanebo HJ, Kennedy BJ, Winchester DP, et al. Gastric cancer: does lymph node dissection alter survival. J Am Coll Surg 1996;183:616-24.
14. Volpe CM, Driscoll DL, Miloro SM, Douglass HO. Survival benefit of extended D2 resection for proximal gastric cancer. J Surg Oncol 1977;64:231-6.
15. Dent DM, Madden MV, Price SK. Randomized comparison of R1 and R2 gastrectomy for gastric cancer. Br J Surg 1988;75:110.
16. Bonenkamp JJ, Songun J, Hermans J, et al. Randomised comparison of morbidity after D1 and D2 dissections for gastric cancer in 996 Dutch patients. Lancet 1995;345:745-8.
17. Bonenkamp JJ, Hermans J, Sasako M, van de Velde CJH. Extended lymph-node dissection for gastric cancer. N Engl J Med 1999;340:908-14.
18. Robertson CS, Chung SCS, Woods SDS, et al. A prospective randomized trial comparing R1 subtotal gastrectomy with R3 total gastrectomy for antral cancer. Ann Surg 1994;22:176-82.
19. Cushieri A, Weeden S, Fielding J, et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Br J Cancer 1999;79:1522-30.
20. Noguchi Y, Imada T, Matsumoto A, et al. Radical surgery for gastric cancer: a review of the Japanese experience. Cancer 1989;64:2053-62.
21. Maruyama K, Okabayashi K, Kinoshita T. Progress in gastric cancer surgery in Japan and its limits of radicality. World J Surg 1987;11:418-25.
22. Brennan MF, Karpeh MS. Surgery for gastric cancer. Semin Oncol 1996;23:352-9.
23. Young JLS, Ries LG, Pollack ES. Cancer patient survival among ethnic groups in the United States. J Natl Cancer Inst 1984;73:341-52.
24. Theuer CP, Kurosaki T, Ziogas A, et al. Asian gastric cancer patients in America exhibit unique clinical features and superior overall and cancer-specific survival. Cancer 2000;89:1883-92.
25. Theuer CP. Asian gastric cancer patients at a Southern California Comprehensive Cancer Center are diagnosed with less advanced disease and have superior stage-stratified survival. Am Surg 2000;66:821-6.
26. Seiffert JE, Price WT, Gordon B. The California tumor registry: a state-of-the-art model for a regionalized, automated population-based registry. Top Health Rec Manage 1990;11:59-73.
27. Cancer Reporting in California. Abstracting and Coding Procedures for Hospitals, Vol. 1. Emeryville, CA: California Tumor Registry, Department of Health Services, Cancer Surveillance Section, 1986.
28. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. ACTA Pathol Microbiol Scand 1965;64:31-49.
29. Sobin LH, Wittekind C. TNM Classification of Malignant Tumors, 5th ed, International Union Against Cancer. New York: John Wiley & Sons, 1997.
30. SAS Institute. SAS/STAT User's Guide, Version 6. Cary, NC: SAS Institute, Inc., 1990.
31. SAS Institute. SAS/STAT Software: Changes and Enhancements, Release 6.07. SAS Technical Report P-229. Cary, NC: SAS Institute, Inc., 1992.
32. Schlemper RJ, Itabashi M, Kato Y, et al. Differences in diagnostic criteria for gastric carcinoma between Japanese and Western pathologists. Lancet 1997;349:1725-9.
33. Lauwers GY, Shimizu M, Correa P, et al. Evaluation of gastric biopsies for neoplasia: differences between Japanese and Western pathologists. Am J Surg Pathol 1999;23:511-8.
34. Mareel M, Vleminckx K, Vermeulen S, et al. E-cadherin expression: a counterbalance for cancer cell invasion. Bull Cancer 1992;79:347-55.
35. Behrens J, Mareel MM, Van Roy F, Birchmeier W. Dissecting tumor cell invasion: epithelial cells acquire invasive properties after the loss of uvomorulin-mediated cell adhesion. J Cell Biol 1989;108:2435-47.
36. Behrens J, Vakaet L, Friis R, et al. Loss of epithelial differentiation and gain of invasiveness correlates with tyrosine phosphorylation of the E-cadherin/β-catenin complex in cells transformed with a temperature-sensitive v-SRC gene. J Cell Biol 1993;120:757-66.
37. Oka H, Shiozaki H, Kobayashi K, et al. Expression of E-cadherin cell adhesion molecules in human breast cancer tissues and its relationship to metastasis. Cancer Res 1993;53:1696-701.
38. Birchmeier W, Weidner KM, Hulsken J, Behrens J. Molecular mechanisms leading to cell junction (Cadherin) deficiency in invasive carcinomas. Semin Cancer Biol 1993;4:231-9.
39. Shiozaki H, Tahara H, Oka H, et al. Expression of immunoreactive E-cadherin adhesion molecules in human cancers. Am J Pathol 1991;139:17-23.
40. Shimoyama Y, Hirohashi S. Expression of E- and P-cadherin in gastric carcinomas. Cancer Res 1991;51:2185-92.
41. Mayer B, Johnson JP, Leitl F, et al. E-cadherin expression in primary and metastatic gastric cancer: down-regulation correlates with cellular de-differentiation and glandular distortion. Cancer Res 1993;53:1690-5.
42. Oka H, Shiozaki H, Kobayashi K, et al. Immunohistochemical evaluation of E-cadherin adhesion molecule expression in human gastric cancer. Virchows Arch A Pathol Anat Histopathol 1992;421:149-56.
43. Nagafuchi A, Shirayoshi Y, Okazaki Y, et al. Transformation of cell adhesion properties by exogenously introduced E-cadherin cDNA. Nature 1987;329:341-3.
44. Jawhari A, Jordan S, Poole S, et al. Abnormal immunoreactivity of the E-cadherin-catenin complex in gastric carcinoma: relationship with patients survival. Gastroenterology 1997;112:46-54.
45. Yonemura Y, Endou Y, Kimura K, et al. Inverse expression of S100A4 and E-cadherin is associated with metastatic potential in gastric cancer. Clin Cancer Res 2000;6:4234-42.
46. Ohene-Abuakwa Y, Noda M, Perenyi M, et al. Expression of the E-cadherin/catenin (α-, β-, and γ-) complex correlates with the macroscopic appearance of early gastric cancer. J Pathol 2000; 192:433-9.
47. Ramesh S, Nash J, McCulloch PG. Reduction in membranous expression of β-catenin and increased cytoplasmic E-cadherin expression predict poor survival in gastric cancer. Br J Cancer 1999;81:1392-7.
48. Karayiannakis AJ, Syrigos KN, Chatzigianni E, et al. E-cadherin expression as a differentiation marker in gastric cancer. Hepatogastroenterology 1998;45:2437-42.
49. Shun CT, Wu MS, Lin JT, et al. An immunohistochemical study of E-cadherin expression with correlations to clinicopathological features in gastric cancer. Hepatogastroenterology 1998;45:944-9.
50. Shino Y, Watanabe A, Yamada Y, et al. Clinicopathologic evaluation of immunohistochemical E-cadherin expression in human gastric carcinomas. Cancer 1995;76:2193-201.
51. Gabbert HE, Mueller W, Schneiders A, et al. Prognostic value of E-cadherin expression in 413 gastric carcinomas. Int J Cancer 1996;69:184-9.
52. Guilford PJ, Hopkins JB, Grady WM, et al. E-cadherin germline mutations define an inherited cancer syndrome dominated by diffuse gastric cancer. Hum Mutat 1999;14:249-55.
53. Richards FM, McKee SA, Rajpar MH, et al. Germline E-cadherin gene (CHD1) mutations predispose to familial gastric cancer and colorectal cancer. Hum Mol Genet 1999;8:607-10.
54. Gayther SA, Gorringe KL, Ramus SJ, et al. Identification of germ-line E-cadherin mutations in gastric cancer families of European origin. Cancer Res 1998;58:4086-9.
55. Kim HC, Wheeler JM, Kim JC, et al. The E-cadherin gene (CDH1) variants T340A and L559V in gastric and colorectal cancer patients in Korea. Gut 2000;47:262-7.
56. Iida S, Akiyama Y, Ichikawa W, et al. Infrequent germ-line mutation of the E-cadherin gene in Japanese familial gastric cancer kindreds. Clin Cancer Res 1999;5:1445-7.
57. Shinmura K, Kohno T, Takahashi M, et al. Familial gastric cancer: clinicopathological characteristics, RER phenotype and germline p53 and E-cadherin mutations. Carcinogenesis 1999;20:1127-31.
58. Stone J, Bevan S, Cunningham D, et al. Low frequency of germline mutations in familial and nonfamilial gastric cancer. Br J Cancer 1999;79:1935-7.
59. Uchino S, Tsuda H, Maruyama K, et al. Overexpression of c-erbB-2 protein in gastric cancer. Cancer 1993;72:3179-84.
60. Nakajima M, Sawada H, Yamada Y, et al. The prognostic significance of amplification and overexpression of c-met and c-erbB-2 in human gastric carcinomas. Cancer 1999;85:1894-902.
61. Kolodziejczyk P, Yao T, Oya M, et al. Long-term follow-up study of patients with gastric adenomas with malignant transformation. Cancer 1994;74:2896-907.
62. Yonemura Y, Ninomiya I, Ohoyama S, et al. Expression of c-erbB-2 oncoprotein in gastric carcinoma. Cancer 1991;67:2914-8.
63. Mizutani T, Onda M, Tokunaga A, et al. Relationship of c-erbB-2 protein expression and gene amplification to invasion and metastasis in human gastric cancer. Cancer 1993;72:2083-8.
64. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer; correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
65. Guerin M, Gabillot M, Mathieu MC, et al. Structure and expression of c-erbB-2 and EGF receptor genes in inflammatory and non-inflammatory breast cancer: prognostic significance. Int J Cancer 1989;43:201-8.
66. Van de Viiver MJ, Peterse JL, Mooi WJ, et al. Neu protein overexpression in breast cancer: association with comedo type-ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med 1988;319:1239-45.
67. Berger MS, Locher GW, Sauer S, et al. Correlation of c-erbB-2 gene amplification and protein expression in human breast Carcinoma with nodal status and nuclear grading. Cancer Res 1988;43:1238-43.
68. Allgayer H, Babic R, Gruetzner KU, et al. C-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. J Clin Oncol 2000;18:2201-9.
69. Albino AP, Jaehne J, Altorki N, et al. Amplification of the HER-2/neu gene in human gastric adenocarcinomas: correlation with primary site. Eur J Surg Oncol 1995;21:56-60.
70. Hilton DA, West KP. C-erbB-2 oncogene product expression and prognosis in gastric carcinoma. J Clin Pathol 1992;45:454-6.
71. Jain S, Filipe MI, Gullick WJ, et al. c-erbB-2 protooncogene expression and its relationship to survival in gastric carcinoma: an immunohistochemical study on archival material. Int J Cancer 1991;48:668-71.
72. McCulloch PG, Ochiai A, O'Dowd GM, et al. Comparison of the molecular genetics of c-erb-B2 and p53 expression in stomach cancer in Britain and Japan. Cancer 1995;75:920-5.
73. Livingstone JI, Yasui W, Tahara E, Wastell C. Are Japanese and European gastric cancer the same biological entity? An immunohistochemical study. Br J Cancer 1995;72:976-80.